Emergent Biosolutions Inc (EBS)vsViatris Inc (VTRS)
EBS
Emergent Biosolutions Inc
$6.80
-3.42%
HEALTHCARE · Cap: $319.43M
VTRS
Viatris Inc
$16.95
-1.05%
HEALTHCARE · Cap: $19.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 1813% more annual revenue ($14.74B vs $770.20M). VTRS leads profitability with a -2.8% profit margin vs -23.0%. EBS appears more attractively valued with a PEG of 0.38. EBS earns a higher WallStSmart Score of 64/100 (C+).
EBS
Buy64
out of 100
Grade: C+
VTRS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.5%
Fair Value
$33.92
Current Price
$6.80
$27.12 discount
Margin of Safety
-84.5%
Fair Value
$8.74
Current Price
$16.95
$8.21 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Revenue surging 66.3% year-over-year
Strong operational efficiency at 28.3%
Reasonable price relative to book value
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
Elevated debt levels
ROE of -1.6% — below average capital efficiency
4.9% revenue growth
ROE of -2.9% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : EBS
The strongest argument for EBS centers on PEG Ratio, Price/Book, Revenue Growth. Revenue growth of 66.3% demonstrates continued momentum. PEG of 0.38 suggests the stock is reasonably priced for its growth.
Bull Case : VTRS
The strongest argument for VTRS centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.
Bear Case : EBS
The primary concerns for EBS are Altman Z-Score, Market Cap, Debt/Equity. Debt-to-equity of 1.70 is elevated, increasing financial risk.
Bear Case : VTRS
The primary concerns for VTRS are Revenue Growth, Return on Equity, EPS Growth.
Key Dynamics to Monitor
EBS profiles as a hypergrowth stock while VTRS is a turnaround play — different risk/reward profiles.
EBS carries more volatility with a beta of 2.34 — expect wider price swings.
EBS is growing revenue faster at 66.3% — sustainability is the question.
VTRS generates stronger free cash flow (329M), providing more financial flexibility.
Bottom Line
EBS scores higher overall (64/100 vs 48/100) and 66.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Emergent Biosolutions Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Emergent BioSolutions Inc., a life sciences company, focuses on providing preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHT). The company is headquartered in Gaithersburg, Maryland.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?